JP Morgan Chase
MREO

JP Morgan Chase’s Mereo BioPharma MREO Stock Holding History

JP Morgan Chase’s Portfolio MREO Stock Details MREO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19.4K Buy
58,531
+36,683
+168% +$11K ﹤0.01% 6745
2026
Q1 		$6.9K Buy
+21,848
New +$9.38K ﹤0.01% 6827
2025
Q2 		– Sell
-365
Closed -$821 – 7437
2025
Q1 		$821 Hold
365
– – ﹤0.01% 6652
2024
Q4 		$1.28K Hold
365
– – ﹤0.01% 6699
2024
Q3 		$1.5K Hold
365
– – ﹤0.01% 6668
2024
Q2 		$1.31K Sell
365
-37,757
-99% -$122K ﹤0.01% 6578
2024
Q1 		$126K Buy
38,122
+19,004
+99% +$64.3K ﹤0.01% 5567
2023
Q4 		$44.2K Sell
19,118
-113,683
-86% -$217K ﹤0.01% 6038
2023
Q3 		$171K Sell
132,801
-171,230
-56% -$227K ﹤0.01% 5159
2023
Q2 		$401K Sell
304,031
-123,102
-29% -$143K ﹤0.01% 4625
2023
Q1 		$302K Buy
427,133
+281,874
+194% +$254K ﹤0.01% 4805
2022
Q4 		$77K Buy
145,259
+132,757
+1,062% +$109K ﹤0.01% 5452
2022
Q3 		$10K Buy
12,502
+7,922
+173% +$9.69K ﹤0.01% 5965
2022
Q2 		$5K Sell
4,580
-8,582
-65% -$6.65K ﹤0.01% 6170
2022
Q1 		$15K Buy
13,162
+368
+3% +$476 ﹤0.01% 6128
2021
Q4 		$21K Buy
12,794
+9,794
+326% +$19.6K ﹤0.01% 6200
2021
Q3 		$7K Buy
+3,000
New +$7.94K ﹤0.01% 6213

Other funds holding MREO

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

JP Morgan Chase's MREO Position: Q2 2026 in Review

JP Morgan Chase increased its Mereo BioPharma (MREO) stake by 168% in Q2 2026, buying an estimated $11K and bringing the position to 58,531 shares worth $19.4K. The position accounts for ﹤0.01% of the portfolio, ranked #6745.

JP Morgan Chase first reported a position in MREO in Q3 2021 and has held it in 17 quarters since. The position peaked at $401K in Q2 2023. 61 funds tracked by Wall St. Rank hold MREO as of Q2 2026.

  • JP Morgan Chase held 58,531 shares of Mereo BioPharma worth $19.4K as of Q2 2026.
  • JP Morgan Chase bought 36,683 Mereo BioPharma shares in Q2 2026, an estimated $11K.
  • Mereo BioPharma made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #6745 holding.
  • JP Morgan Chase first reported a position in Mereo BioPharma in Q3 2021 and has held it in 17 quarters since.
  • JP Morgan Chase's Mereo BioPharma position peaked at $401K in Q2 2023.
  • 61 funds tracked by Wall St. Rank held Mereo BioPharma as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.